Bristol-Myers Squibb Company (NYSE: BMY) is a Healthcare company (Drug Manufacturers - General) with a market capitalization of $129.7B. The Maz Rating grades it against the other companies in its sector.
Bristol-Myers Squibb Company's current Maz Rating and its five factor grades are for members: log in to see them.
At $63.43, Bristol-Myers Squibb Company trades at 14.0x trailing earnings, 2.6x sales and 5.5x book value, with an EV/EBITDA of 10.9. Over the last twelve months it generated about $50.0B of revenue and $9.2B of net income. It runs a gross margin of 69.2%, an operating margin of 26.1% and a net margin of 18.5%. It shows return on equity of 43.9%, return on invested capital of 14.9% and a free cash flow yield of 7.2%. On the balance sheet: a debt-to-equity ratio of 1.91 and a current ratio of 1.59. Over the past 52 weeks the share price ranged from $45.27 to $68.64, with a beta of 0.23.
Bristol-Myers Squibb Company pays a dividend yielding 3.97%, with 55% of earnings paid out. Its Maz Dividend Score is 3.10 out of 5, ranked against the other dividend payers in its sector (Safety 1.83, Growth 1.90, Yield 4.90, Consistency 4.83).
42 Wall Street analyst ratings cover the stock: 19 Buy, 21 Hold and 2 Sell, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Bristol-Myers Squibb Company (BMY) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 33.5% / 30% · (Cash+Inv) / Mkt Cap (36m) 10.1% / 30% · Interest income / Revenue 0.00% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 33.5% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 9.78% / 33% · Receivables / Mkt Cap (36m) 8.27% / 49% · Interest income / Revenue 0.00% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 33.5% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 9.78% / 33.33% · Receivables / Mkt Cap (24m) 8.27% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 49.8% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 12.7% / 33.33% · Receivables / Avg Assets (4Q) 13.5% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 48.5% / 33.33% · (Cash+ST Inv) / Total Assets 14.2% / 33.33% · (Cash+Recv) / Total Assets 26.2% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
No. As of September 2026, Bristol-Myers Squibb Company (BMY) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Bristol-Myers Squibb Company is over the AAOIFI limit on Debt / Mkt Cap (36m).
Bristol-Myers Squibb Company reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.